inovio pharmaceuticals american biotechnology company focused discovery development commercialization synthetic dna products treating cancers infectious diseases april inovio among companies academic centers research organizations developing vaccine candidate treating people infected total vaccine candidates development june inovio technology based inserting engineered dna cells becomes transcribed mrna translated proteins proteins encoded dna elicit immune response antigens cancers viruses stimulating production cells antibodies aid technology targeted specific types cancer immune diseases produced meeting white house coronavirus task force march ceo joseph kim said inovio scientists designed vaccine candidate coronavirus january three hours virus genetic sequence first shareholders sued inovio august claiming exaggerated evidence coronavirus vaccines efficacy order boost stock inovio licensed certain patented technology relating delivery genebased therapeutics skin well patents involving delivery genes drugs via ex vivo intratumoral intramuscular electroporation exvivo patents relevant delivery genes dendritic stem sometime publication february inovio assigned patent apparatus provides injecting fluid body tissue apparatus comprising hollow needle fluid delivery means wherein apparatus adapted actuate fluid delivery means use automatically inject fluid body tissue insertion needle said body facilitate use potential products inovio manufactures proprietary injection device called cellectra company describes providing brief electrical pulse reversibly open small pores cell allow plasmids enter overcoming key limitation dna nucleic acid approaches small device runs aa batteries designed use field difficult conditions june anticipation inovio vaccine candidate becoming successful us department defense invested million develop cellectra handheld device preorder undisclosed number doseescalation phase clinical trial assess safety intramuscular injection healthy adults inovio vaccine candidate also called development middle east respiratory syndrome mers coronavirus proved safe mild symptoms adverse trial also demonstrated immunogenicity doseindependent immune responses detected subjects two vaccinations durable year inovio involved along partners geneone life science attempt control zika virus outbreak miami fact first initiate human zika dna vaccine trial safety tolerability immunogenicity healthy adults trials estimated completion date november puerto rico zika emergency declared study previously healthy adults using proprietary preliminary results miami trial selfreported end february receiving details genetic sequence coronavirus inovio announced produced preclinical dnabased vaccine potential therapy inovio competition develop coronavirus vaccine numerous companies conducting preclinical earlystage human research vaccine candidates late april inovio began phase trial vaccine candidate may inovio announced results preclinical studies dna vaccine plans initiate phase iii studies vaccine incorporates common overlapping mutations several variants concern isolated several different countries including brazil january coalition epidemic preparedness innovations cepi announced would grant million inovio development vaccine inovio partnerships develop vaccine candidate cepi south korean national institute health international vaccine inovio collaborating beijing advaccine biotechnology co chinese biotech order speed acceptance regulatory authorities china plans begin human clinical trials candidate vaccine china first half inovio partnerships manufacturers scale production vaccine preliminary efficacy trials april company began human phase safety studies lead vaccine united states phase iii trial south korea test immunization april us department defense discontinued funding future phase iii trials company planning conduct phase iii trials outside united statescitation needed july decided conduct phase trials partnership beijing based advaccine pharmaceutical early june inovio partnered international vaccine institute seoul national university south korea advance human research phase iii safety efficacy trial conducted participants seoul national university hospital beginning trial funded coalition epidemic preparedness innovations supported korea centers disease control prevention korea national institute inovio formerly known electrofect founded oslo norway company renamed inovio october httpsenwikipediaorgwikiinoviopharmaceuticals